Narrative review discusses CRISPR strategies for MRSA biofilm infections with noted limitations

Photo by Navy Medicine / Unsplash

Frontiers in Medicine Published May 13, 2026 Medically reviewed May 13, 2026 DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Consider CRISPR strategies for MRSA biofilms as promising but requiring further refinement in delivery and target selection.

This narrative review evaluates the potential of CRISPR-based strategies, such as Cas9, Cas12a, and Cas13, for treating Methicillin-resistant Staphylococcus aureus biofilm-associated infections. The scope covers targeting resistance genes, virulence factors, and regulatory networks within these complex bacterial structures. The authors synthesize early evidence from emerging in vivo studies, which indicate a reduction of bacterial burden and impairment of biofilm integrity. No specific effect sizes or absolute numbers are reported for these outcomes.

The review highlights several critical limitations that currently hinder clinical translation. These include limited penetration into mature biofilms, delivery inefficiency, off-target activity, immunogenicity, resistance evolution, and regulatory uncertainty. The authors do not report specific adverse event rates or serious adverse events, though they list off-target activity and immunogenicity as known concerns. The review does not provide data on discontinuations or tolerability.

The practice relevance is described as promising but still developing. The authors argue that further refinement is needed in delivery design, target selection, and translational validation before these interventions can be widely adopted. The review concludes that while the technology shows potential, it requires substantial additional work to overcome current technical and biological barriers.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

Methicillin-resistant Staphylococcus aureus exhibits heightened tolerance to antimicrobial therapy through restricted drug penetration, extracellular polymeric substance-mediated protection, metabolic heterogeneity, and persister cell formation, limiting the effectiveness of current treatment strategies. CRISPR-Cas systems have emerged as programmable antimicrobial tools capable of targeting resistance genes, virulence determinants, and regulatory pathways; however, existing approaches remain largely gene-centric and insufficiently integrated with the biological complexity of biofilm-associated infections. This review aims to provide a comprehensive and integrative analysis of CRISPR-based strategies for targeting MRSA biofilms by linking molecular CRISPR mechanisms with key biofilm processes and evaluating their translational potential. CRISPR-Cas systems have emerged as programmable antimicrobial platforms with the ability to selectively target resistance genes, virulence factors, and regulatory networks. In MRSA biofilms, these systems are increasingly being explored for their potential to disrupt biofilm-associated determinants and weaken the molecular basis of persistence. Recent advances involving Cas9, Cas12a, and Cas13 highlight the potential of CRISPR-based targeting to interfere with resistance mechanisms, quorum sensing pathways, and structural components relevant to biofilm stability. Emerging in vivo studies, particularly those using engineered bacteriophages and localized delivery systems, provide early evidence that CRISPR-based strategies can reduce bacterial burden and impair biofilm integrity under physiologically relevant conditions. Nevertheless, significant barriers remain, including limited penetration into mature biofilms, delivery inefficiency, off-target activity, immunogenicity, resistance evolution, and regulatory uncertainty. Ultimately, CRISPR-based interventions represent a promising but still developing approach for the control of MRSA biofilm-associated infections, requiring further refinement in delivery design, target selection, and translational validation.